Larimar Therapeutics, Inc. Common Stock (LRMR) Stock Price
LRMRStock
$1.99−53.40%52W
Market Cap$206.21M
P/E—
PEG Ratio—
Div yield—
Beta0.71
LRMR Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-69.15%
Price vs S&P 500 (4W)-46.85%
VGM Score21.83
LRMR Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.38 | -$0.30 | +20.22%(+$0.08) | |
| Q1 2026 | -$0.59 | -$0.31 | +47.90%(+$0.29) | |
| Q4 2025 | -$0.55 | -$0.73 | -33.78%(-$0.18) | |
| Q3 2025 | -$0.42 | -$0.61 | -44.20%(-$0.19) | |
| Q2 2025 | -$0.49 | -$0.41 | +15.64%(+$0.08) |
LRMR Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.44
4.44
4.41
4.41
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
LRMRLarimar Therapeutics, Inc. Common Stock | — | — | D | — | — | — | — | $1.99 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Larimar Therapeutics, Inc. Common Stock
Larimar Therapeutics is a clinical-stage biotechnology company developing treatments for rare genetic diseases using its proprietary cell-penetrating peptide technology platform. Its lead candidate, CTI-1601, is designed to deliver a critical missing protein directly to the mitochondria of patients with Friedreich's ataxia via subcutaneous injection. The company is advancing a novel treatment approach to address a significant unmet medical need in the rare disease space.